Can bupropion (Wellbutrin) be used for e‑cigarette (vaping) cessation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Bupropion for Vaping Cessation

Yes, bupropion (Wellbutrin) can be used for e-cigarette cessation, though the evidence is extrapolated from traditional smoking cessation studies rather than vaping-specific trials.

Evidence Base and Rationale

The use of bupropion for vaping cessation is supported by its established efficacy for nicotine dependence treatment, though no direct RCTs exist specifically for e-cigarette users. Bupropion is FDA-approved for smoking cessation in adults and works by inhibiting dopamine and norepinephrine reuptake while also blocking nicotinic acetylcholine receptors 1, 2. This mechanism addresses the underlying nicotine addiction regardless of delivery method.

Efficacy for Nicotine Cessation

For traditional smoking cessation, bupropion demonstrates:

  • Odds ratio of 2.07 (95% CI 1.75-2.45) versus placebo, translating to approximately 3 additional quitters per 100 treated 1
  • Relative risk of 1.62 (95% CI 1.49-1.76) across 44 trials 1
  • Efficacy similar to nicotine patch but less than varenicline 3, 4

The 2025 American Thoracic Society guidelines suggest bupropion for adolescents (ages 10-18) with nicotine use, noting that "the panel judged that the potential benefits of bupropion outweigh the risks" despite very low certainty evidence 5. This recommendation was based on years of clinical experience and the drug's established safety profile in pediatric populations.

Dosing Protocol

Standard dosing for nicotine cessation 1:

  • Initiate 1-2 weeks prior to quit date
  • Days 1-3: 150 mg orally once daily
  • Day 4 through 7-12 weeks: 150 mg orally twice daily (if tolerated)
  • Maximum: 300 mg per day
  • Duration: 7-12 weeks initially, may extend to 6-12 months to prevent relapse

Critical Safety Considerations

Absolute Contraindications 1, 2:

  • Seizure disorder or conditions increasing seizure risk (stroke, brain metastases, CNS tumor, severe head injury, arteriovenous malformation)
  • Current or prior bulimia or anorexia nervosa (higher seizure incidence)
  • Concurrent MAO inhibitor use
  • Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs
  • Closed-angle glaucoma

Seizure Risk

The seizure risk is approximately 0.1% (1 in 1,000) and is dose-related 1, 6. Risk increases with:

  • Doses exceeding 300 mg/day
  • Concomitant medications lowering seizure threshold (antipsychotics, tricyclic antidepressants, theophylline, systemic corticosteroids)
  • Metabolic disorders (hypoglycemia, hyponatremia, severe hepatic impairment)
  • Illicit drug use

Neuropsychiatric Effects

While the FDA black box warning addresses neuropsychiatric events, the EAGLES trial (n=8,144) found no significant increase in neuropsychiatric adverse events with bupropion versus nicotine patch or placebo 1. However, monitor for:

  • Depression and suicidal ideation/behavior
  • Agitation, hostility, aggression
  • Anxiety, panic attacks
  • Psychosis, hallucinations, delusions

Discontinue immediately if severe neuropsychiatric symptoms emerge 2.

Other Adverse Effects

  • Serious adverse events occur in approximately 3% of patients 3
  • Moderate-certainty evidence suggests bupropion may slightly increase SAE rates (1 additional per 100 treated), though credibility intervals include no difference 3
  • Common side effects: insomnia, dry mouth, headaches, nausea 1

Practical Application for Vaping Cessation

When to Use Bupropion:

  1. First-line option for patients with moderate-to-severe nicotine dependence from vaping
  2. Particularly beneficial for patients with comorbid depression 1
  3. Alternative to varenicline when varenicline is contraindicated or not tolerated
  4. Combination with NRT may be considered as subsequent therapy if monotherapy fails 1

Monitoring Requirements:

  • Screen for contraindications before initiating
  • Monitor for neuropsychiatric symptoms, especially in first few months
  • Assess for seizure risk factors
  • Evaluate alcohol and benzodiazepine use patterns
  • Consider dose adjustments in hepatic or renal impairment

Important Caveats:

  • Do not combine with other bupropion-containing products (Zyban, Wellbutrin SR, Aplenzin) 2
  • Advise patients to minimize or avoid alcohol due to increased seizure risk 2
  • Swallow tablets whole—do not crush, divide, or chew 2
  • If dose missed, do not double up (seizure risk) 2

Emerging Evidence

One small study (n=24) explored bupropion/zonisamide combination specifically for switching from combustible cigarettes to ENDS, achieving 33% complete abstinence with minimal side effects 7. While intriguing, this requires larger RCTs before clinical adoption.

The bottom line: Bupropion is a reasonable pharmacotherapy option for vaping cessation based on its established efficacy for nicotine dependence, though direct evidence for e-cigarette users is lacking. Screen carefully for contraindications, particularly seizure risk factors, and monitor closely for neuropsychiatric effects.

References

1
Guideline

smoking cessation, version 1.2016, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2016

Related Questions

What is the appropriate initiation, titration, and monitoring plan for bupropion maintenance therapy in a 27-year-old woman with mixed anxiety and depressive disorder?
What is the appropriate way to taper and discontinue escitalopram (Lexapro) and increase bupropion (Wellbutrin) dosage in a 39‑year‑old female with major depressive disorder and generalized anxiety disorder who is experiencing bruxism from escitalopram?
In a 41‑year‑old patient with an unspecified mood disorder taking Auvelity (dextromethorphan‑bupropion) 45‑105 mg daily and Caplyta (lumateperone) 10.5 mg daily, who has anemia (low RBC, low hemoglobin, low hematocrit), elevated fasting glucose, high blood urea nitrogen with mildly elevated creatinine, normal liver enzymes, and normal thyroid‑stimulating hormone, what is the appropriate work‑up and management?
In a 59-year-old female nursing-home resident with depression, anxiety, and a history of alcohol abuse who is taking bupropion XL (bupropion) 300 mg daily, escitalopram 20 mg daily, trazodone 100 mg at bedtime and 25 mg in the morning, amphetamine/dextroamphetamine (Adderall) 10 mg daily, and divalproex sodium (Depakote) 250 mg twice daily, and who now presents with worsening depression, social isolation, increased daytime sleepiness, and anhedonia, what is the optimal psychotropic treatment approach?
In a 23-year-old male with anxiety and depression who smokes and wishes to quit, is bupropion (Wellbutrin) an appropriate treatment choice?
What is the recommended treatment and work‑up for paraneoplastic cerebellar degeneration?
What is the appropriate treatment for a cutaneous fungal infection presenting as an open ulcer?
What is the most appropriate sleep aid to add to a patient taking venlafaxine?
What volume of sterile 0.9% sodium chloride solution is recommended for continuous bladder irrigation?
Is bupropion safe for use while breastfeeding?
What is the pathophysiology of reactive hypoglycemia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.